100 results
6-K
EX-99.1
PRQR
ProQR Therapeutics N.V
23 Apr 24
Current report (foreign)
7:06am
and progress our clinical programs; the ability to secure, maintain and realize the intended benefits of collaborations with partners, including
6-K
EX-99.1
PRQR
ProQR Therapeutics N.V
19 Apr 24
ProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio
7:06am
and realize the intended benefits of collaborations with partners, including the collaboration with Lilly; the possible impairment of, inability
6-K
EX-99.1
PRQR
ProQR Therapeutics N.V
13 Mar 24
ProQR Announces Year End 2023 Operating and Financial Results
7:10am
benefits thereof, and our financial position and cash-runway. Forward-looking statements are based on management's beliefs and assumptions … and realize the intended benefits of collaborations with partners, including the collaboration with Lilly; the possible impairment of, inability to obtain
6-K
EX-99.1
PRQR
ProQR Therapeutics N.V
15 Feb 24
ProQR Announces Japanese Axiomer™ Patent Upheld Following Opposition Against Its Leading IP Estate for ADAR-mediated RNA Editing
7:46am
suppliers or contract manufacturers; the ability to secure, maintain and realize the intended benefits of collaborations with partners, including
6-K
EX-99.1
ifztkorsfz
19 Jan 24
ProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024
7:08am
6-K
EX-99.1
sqpxi 61nz
5 Jan 24
Current report (foreign)
7:08am
6-K
EX-99.1
0rk180z
8 Dec 23
ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic Assets
7:37am
6-K
dqtbdf3qasmts1nnn9e
8 Dec 23
ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic Assets
7:37am
6-K
EX-10.1
31m9hw41qjc1q
8 Dec 23
ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic Assets
7:37am
6-K
EX-99.2
snfiqhcacapj63
7 Nov 23
Current report (foreign)
10:00am
6-K
EX-99.1
z99v 86vh2ox6
27 Sep 23
ProQR Therapeutics Provides Update on Ophthalmic Assets
7:06am
6-K
EX-99.2
cnkvqvxt8r3b4xdl7
3 Aug 23
Current report (foreign)
7:15am
6-K
EX-99.1
byl dbulnn86rxu8army
1 Aug 23
ProQR Therapeutics and Laboratoires Théa Announce Agreement for Théa to Acquire ProQR’s Sepofarsen and Ultevursen Ophthalmic Assets
7:15am
6-K
83dl yf2ah
1 Aug 23
ProQR Therapeutics and Laboratoires Théa Announce Agreement for Théa to Acquire ProQR’s Sepofarsen and Ultevursen Ophthalmic Assets
7:15am
6-K
EX-99.2
k7jllnvf zpi7
16 May 23
Current report (foreign)
7:15am
424B5
3dbo0 jkth1nyua
24 Apr 23
Prospectus supplement for primary offering
4:30pm
6-K
EX-99.1
i6f8cjmm5g1w6 kegl
18 Apr 23
Current report (foreign)
8:05am
F-3
ypdhj8k i2
29 Mar 23
Shelf registration (foreign)
4:53pm